Evidence map›Paper›PMID 29783621›Full record

ReviewCancers2018

[

Salim Kanoun, Cedric Rossi, Olivier Casasnovas

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Efficiency of PET-CT in Reducing the Usage of Radiotherapy in Childhood Hodgkin Lymphoma: A Single Center Experience.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Radiomic Features ofContrast media & molecular imaging · 2021
    Article
  8. Deep learning convolutional neural network (DLCNN): unleashing the potential ofAmerican journal of nuclear medicine and molecular imaging · 2021
    Article
  9. Isolated Splenic Tuberculosis Masquerading as Disease Progression of Hodgkin's Lymphoma on InterimIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Salim KanounNuclear Medicine Department, Institut Claudius Regaud, 31100 Toulouse, France. Salim.kanoun@gmail.com.ORCID 0000-0002-8592-3773
Cedric RossiCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, 31100 Toulouse, France. cedric.rossi@chu-dijon.fr.
Olivier CasasnovasHématologie Clinique, CHU Dijon, 21000 Dijon, France. olivier.casasnovas@chu-dijon.fr.
Centre National de la Recherche Scientifique · FRCHU Dijon Bourgogne · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Functional imaging using 18-fluorodeoxyglycose ([

Indexed as

[18F]FDGHodgkin Lymphomainterim PETPET/CTstagingtotal metabolic tumor volumetreatment response

Identifiers

PMID29783621
PMCPMC5977118
OpenAlexW2804618064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.